m
Recent Posts
Connect with:
Monday / May 23.
HomeminewsBehcet’s Disease Uveitis New Study

Behcet’s Disease Uveitis New Study

A clinical trial in the United States will investigate the safety and efficacy of gevokizumab for the treatment of patients with Behcet’s disease uveitis.

Behcet’s disease causes chronic vasculitis and left without treatment, can lead to retinal detachment, vitreous hemorrhage, glaucoma and eventually, blindness.

The Eyeguard-US trial will be undertaken by biotechnology company Xoma. Twenty-eight patients will be administered gevokizumab, in an open-label trial. Those who respond to gevokizumab by day 28 will be randomly assigned in a 1:1, double-masked to either gevokizumab 60 mg or placebo. The treatment will be administered subcutaneously once a month and Xoma states, the study’s primary endpoint is the time to first ocular exacerbation following randomisation.

“Opening Eyeguard-US is a crucial step in our strategy to pursue Behçet’s disease uveitis as our first indication for gevokizumab in the U.S.,” said John Varian, Chief Executive Officer of XOMA.

DECLARATION

DISCLAIMER : THIS WEBSITE IS INTENDED FOR USE BY HEALTHCARE PROFESSIONALS ONLY.
By agreeing & continuing, you are declaring that you are a registered Healthcare professional with an appropriate registration. In order to view some areas of this website you will need to register and login.
If you are not a Healthcare professional do not continue.